12:00 AM
 | 
Oct 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NGR-hTNF: Phase II data

In an open-label, Italian Phase II trial (Study NGR008) in 40 patients, IV NGR-hTNF led to a median overall survival of 8.9 months and 1- and 2-year survival rates of 27% and 17%,...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >